Global Allergy Diagnostics Market Report 2022: Market to Reach US$5.7 Billion by 2026 - Increasing Prevalence and Incidence of Allergic Disorders to Drive the Demand
07 juin 2022 05h48 HE
|
Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergy Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Allergy Diagnostics...
Global Allergen Blocker Market Report to 2027 - Featuring Trutek, Prestige Brands and Ecology Works Among Others
07 juin 2022 04h53 HE
|
Research and Markets
Dublin, June 07, 2022 (GLOBE NEWSWIRE) -- The "Allergen Blocker Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027" report has been added to ResearchAndMarkets.com's...
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
24 mai 2022 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Worldwide Allergy Immunotherapy Industry to 2028 - Increasing Approval of Allergy Immunotherapy by Regulatory Authorities are Driving Growth
28 avr. 2022 07h23 HE
|
Research and Markets
Dublin, April 28, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunotherapy Market, by Treatment Type, by Allergy Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity...
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
06 avr. 2022 08h30 HE
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Eleven Dose Levels Patient Treatment Now Ongoing in Cohort 3 Intrommune Expands Study Scope to Explore MTD NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune...
Intrommune Reports Positive Update from Ongoing Phase 1 Study in Peanut Allergy
08 févr. 2022 08h30 HE
|
Intrommune Therapeutics
INT301 Met Safety Goals Across Four Dose Levels in Cohort 1 Patient Treatment Now Ongoing in Fully Enrolled Cohort 2 Intrommune Launches Series B Financing NEW YORK, Feb. 08, 2022 (GLOBE...
Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
25 janv. 2022 05h23 HE
|
Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
21 déc. 2021 09h39 HE
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Therapeutic Dog Food Market Size Worth $8,949.52 Million, Globally, by 2028 at 5.6% CAGR - Exclusive Report by The Insight Partners
16 déc. 2021 05h41 HE
|
The Insight Partners
New York, Dec. 16, 2021 (GLOBE NEWSWIRE) -- According to the new market research report "Therapeutic Dog Food Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Dry Food,...
Center for Allergy & Asthma of Georgia Partners with Southern Ear, Nose, Throat and Allergy Physicians
19 nov. 2021 09h00 HE
|
Cross Keys Capital, LLC.
Fort Lauderdale, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Cross Keys Capital, a leading investment bank to physician group practices, healthcare services and technology companies nationally, is pleased to...